ZAI LAB LIMITED (ZLAB) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
36/69
2.6 / 5 stars
All 69 Win/Lose results and 51 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseZLAB / S&P 1.01% / 15.20% |
LoseZLAB / S&P 4.39% / 15.00% |
LoseZLAB / S&P -10.00% / 50.40% |
| 2026-Q11/3 |
WinZLAB / S&P 6.63% / -4.33% |
LoseZLAB / S&P 7.44% / 11.30% |
LoseZLAB / S&P -29.17% / 27.70% |
| 2025-Q41/3 |
LoseZLAB / S&P -47.95% / 2.65% |
WinZLAB / S&P 14.98% / 9.00% |
LoseZLAB / S&P -36.00% / 13.40% |
| 2025-Q31/3 |
LoseZLAB / S&P -3.09% / 8.12% |
WinZLAB / S&P 23.58% / 4.61% |
LoseZLAB / S&P -29.63% / 13.45% |
| 2025-Q21/3 |
LoseZLAB / S&P -3.24% / 10.94% |
WinZLAB / S&P 31.89% / 4.83% |
LoseZLAB / S&P -33.33% / 10.63% |
| 2025-Q12/3 |
WinZLAB / S&P 37.99% / -4.27% |
WinZLAB / S&P 42.96% / 4.98% |
LoseZLAB / S&P -31.43% / 10.57% |
| 2024-Q42/3 |
WinZLAB / S&P 8.49% / 2.41% |
WinZLAB / S&P 49.08% / 5.25% |
LoseZLAB / S&P -28.57% / 6.15% |
| 2024-Q32/3 |
WinZLAB / S&P 39.30% / 5.89% |
WinZLAB / S&P 34.99% / 5.89% |
LoseZLAB / S&P -12.90% / 6.11% |
| 2024-Q22/3 |
WinZLAB / S&P 8.18% / 4.28% |
WinZLAB / S&P 28.58% / 5.38% |
LoseZLAB / S&P -26.83% / 5.12% |
| 2024-Q11/3 |
LoseZLAB / S&P -41.38% / 10.56% |
WinZLAB / S&P 26.90% / 5.71% |
LoseZLAB / S&P -16.67% / 5.59% |
| 2023-Q42/3 |
WinZLAB / S&P 12.42% / 11.69% |
WinZLAB / S&P 25.41% / 6.81% |
LoseZLAB / S&P -23.91% / 7.78% |
| 2023-Q31/3 |
LoseZLAB / S&P -12.33% / -3.27% |
WinZLAB / S&P 35.11% / 7.52% |
LoseZLAB / S&P -50.79% / -5.03% |
| 2023-Q21/3 |
LoseZLAB / S&P -16.63% / 8.74% |
WinZLAB / S&P 38.69% / 9.50% |
LoseZLAB / S&P -26.79% / -8.57% |
| 2023-Q12/3 |
WinZLAB / S&P 8.34% / 7.50% |
WinZLAB / S&P 34.85% / 10.77% |
LoseZLAB / S&P -30.00% / -15.69% |
| 2022-Q41/2 |
LoseZLAB / S&P -10.23% / 7.56% |
WinZLAB / S&P 47.58% / 11.88% |
No dataZLAB / S&P / -17.99% |
| 2022-Q32/2 |
WinZLAB / S&P -1.38% / -4.88% |
WinZLAB / S&P 68.87% / 13.47% |
No dataZLAB / S&P / -1.41% |
| 2022-Q21/2 |
LoseZLAB / S&P -21.15% / -16.10% |
WinZLAB / S&P 108.26% / 13.71% |
No dataZLAB / S&P / 11.04% |
| 2022-Q11/2 |
LoseZLAB / S&P -30.02% / -4.60% |
WinZLAB / S&P 179.57% / 15.97% |
No dataZLAB / S&P / 42.23% |
| 2021-Q41/2 |
LoseZLAB / S&P -40.36% / 11.03% |
WinZLAB / S&P 194.34% / 15.00% |
No dataZLAB / S&P / 96.40% |
| 2021-Q31/2 |
LoseZLAB / S&P -40.45% / 0.58% |
WinZLAB / S&P 199.24% / 10.77% |
No dataZLAB / S&P / 69.42% |
| 2021-Q21/1 |
WinZLAB / S&P 32.65% / 8.55% |
No dataZLAB / S&P / 6.58% |
No dataZLAB / S&P / 51.81% |
| 2021-Q10/1 |
LoseZLAB / S&P -1.41% / 6.17% |
No dataZLAB / S&P / -1.06% |
No dataZLAB / S&P / 7.39% |
| 2020-Q41/1 |
WinZLAB / S&P 62.73% / 12.15% |
No dataZLAB / S&P / -3.72% |
No dataZLAB / S&P / -33.42% |
| 2020-Q30/1 |
LoseZLAB / S&P 1.27% / 8.93% |
No dataZLAB / S&P / -2.04% |
No dataZLAB / S&P / -27.10% |
| 2020-Q21/1 |
WinZLAB / S&P 59.54% / 20.54% |
No dataZLAB / S&P / -0.46% |
No dataZLAB / S&P / -27.11% |
| 2020-Q11/1 |
WinZLAB / S&P 23.78% / -19.60% |
No dataZLAB / S&P / 3.47% |
No dataZLAB / S&P / -14.75% |
| 2019-Q41/1 |
WinZLAB / S&P 28.56% / 9.07% |
No dataZLAB / S&P / 5.36% |
No dataZLAB / S&P / 2.99% |
| 2019-Q30/1 |
LoseZLAB / S&P -7.23% / 1.70% |
No dataZLAB / S&P / 5.02% |
No dataZLAB / S&P / 0.21% |
| 2019-Q21/1 |
WinZLAB / S&P 18.16% / 4.30% |
No dataZLAB / S&P / 6.64% |
No dataZLAB / S&P / 8.65% |
| 2019-Q11/1 |
WinZLAB / S&P 27.09% / 13.65% |
No dataZLAB / S&P / 8.12% |
No dataZLAB / S&P / 14.29% |
| 2018-Q41/1 |
WinZLAB / S&P 19.20% / -13.52% |
No dataZLAB / S&P / 9.05% |
No dataZLAB / S&P / 18.23% |
| 2018-Q30/1 |
LoseZLAB / S&P -16.22% / 7.71% |
No dataZLAB / S&P / 10.21% |
No dataZLAB / S&P / 19.06% |
| 2018-Q21/1 |
WinZLAB / S&P 8.90% / 3.43% |
No dataZLAB / S&P / 9.03% |
No dataZLAB / S&P / 14.46% |
| 2018-Q11/1 |
WinZLAB / S&P 0.57% / -0.76% |
No dataZLAB / S&P / 7.68% |
No dataZLAB / S&P / 12.46% |
| 2017-Q40/1 |
LoseZLAB / S&P -21.37% / 6.64% |
No dataZLAB / S&P / 7.03% |
No dataZLAB / S&P / 13.82% |
| 2017-Q30/0 |
No dataZLAB / S&P / 4.48% |
No dataZLAB / S&P / 5.68% |
No dataZLAB / S&P / 17.57% |
| 2017-Q20/0 |
No dataZLAB / S&P / 3.09% |
No dataZLAB / S&P / 4.83% |
No dataZLAB / S&P / 17.74% |
| 2017-Q10/0 |
No dataZLAB / S&P / 6.07% |
No dataZLAB / S&P / 3.67% |
No dataZLAB / S&P / 13.32% |
| 2016-Q40/0 |
No dataZLAB / S&P / 3.82% |
No dataZLAB / S&P / 2.09% |
No dataZLAB / S&P / 7.05% |
| 2016-Q30/0 |
No dataZLAB / S&P / 3.85% |
No dataZLAB / S&P / 0.20% |
No dataZLAB / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ZLAB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -18.97% | 20.78% |
| Annualized return | -18.97% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ZLAB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -81.78% | 83.14% |
| Annualized return | -28.86% | 12.86% |
10Y · 2017-09-20 to 2026-08-27
| Metric | ZLAB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -3.97% | 319.30% |
| Annualized return | -0.40% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |